Tocofersolan

Tocofersolan
Clinical data
Trade names	Vedrop
Other names	Tocophersolan (USANUS)
AHFS/Drugs.com	UK Drug Information
Legal status
Legal status	UK:POM(Prescription only); EU:Rx-only;
Identifiers
DrugBank	DB11635;
KEGG	D06174;
CompTox Dashboard(EPA)	DTXSID90872278 DTXSID1048623, DTXSID90872278;
ECHA InfoCard	100.123.651

Tocofersolan
Names
	IUPAC name α-Hydro-ω-{[4-oxo-4-({(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-yl}oxy)butanoyl]oxy}poly(oxyethylene)
	Other names Tocofersolan; Vitamin E PEG succinate; α-Tocopherol polyethylene glycol succinate (TPGS); Liqui-E
Identifiers
CAS Number	9002-96-4;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL2355578;
ChemSpider	64498;
DrugBank	DB11635;
ECHA InfoCard	100.123.651
EC Number	618-345-6;
PubChemCID	9938056;
UNII	O03S90U1F2;
CompTox Dashboard(EPA)	DTXSID90872278 DTXSID1048623, DTXSID90872278;
	InChI InChI=1S/C35H58O6/c1-24(2)12-9-13-25(3)14-10-15-26(4)16-11-20-35(8)21-19-30-29(7)33(27(5)28(6)34(30)41-35)40-32(38)18-17-31(37)39-23-22-36/h24-26,36H,9-23H2,1-8H3 Key: AOBORMOPSGHCAX-UHFFFAOYSA-N; InChI=1/C35H58O6/c1-24(2)12-9-13-25(3)14-10-15-26(4)16-11-20-35(8)21-19-30-29(7)33(27(5)28(6)34(30)41-35)40-32(38)18-17-31(37)39-23-22-36/h24-26,36H,9-23H2,1-8H3 Key: AOBORMOPSGHCAX-UHFFFAOYAU;
	SMILES O=C(OCCO)CCC(=O)Oc2c(c(c1OC(CCc1c2C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)C;
Properties
Chemical formula	(C2H4O)nC33H54O5
Molar mass	Variable
Pharmacology
ATC code	A11HA08(WHO)
License data	EUEMA:by INN;
	Except where otherwise noted, data are given for materials in theirstandard state(at 25 °C [77 °F], 100 kPa). verify(what is?) Infobox references

Tocofersolan(INN) ortocophersolan,also referred to asTPGS(fortocopherolpolyethylene glycol succinate), is a synthetic water-soluble version ofvitamin E.Natural forms of vitamin E are fat soluble, but not water-soluble. Tocofersolan ispolyethylene glycolderivative ofα-tocopherolthat enables water solubility.

Tocofersolan is used as a vitamin E supplement or to treat vitamin E deficiency in individuals who cannot absorb fats due to disease.^[3] On 24 July 2009 theEuropean Medicines Agencyapproved tocofersolan under the trade nameVedrop50 mg/ml oral solution for the treatment of vitamin E deficiency due to digestivemalabsorptioninpaediatricpatients withcongenitalor hereditary chroniccholestasis,from birth (in term newborns) to 16 or 18 years of age (depending on the region).^[4]

Tocofersolan is also used in cosmetics and pharmaceuticals as anantioxidant.^[5]

References[edit]

^"Vedrop 50 mg/ml oral solution - Summary of Product Characteristics (SmPC)".(emc).19 June 2019.Retrieved24 July2020.
^"Vedrop EPAR".European Medicines Agency(EMA).Retrieved24 July2020.
^"Tocophersolan Oral".WebMD.
^"Vedrop Summary of Product Characteristics "(PDF).European Medicines Agency.^{[permanent dead link]}
^Ash M, Ash I (2004).Handbook of Preservatives.Synapse Info Resources. p. 568.ISBN 1-890595-66-7.

Thisdrugarticle relating to thegastrointestinal systemis astub.You can help Wikipedia byexpanding it.

[1] "Vedrop 50 mg/ml oral solution - Summary of Product Characteristics (SmPC)".(emc).19 June 2019.Retrieved24 July2020.

[2] "Vedrop EPAR".European Medicines Agency(EMA).Retrieved24 July2020.

[3] "Tocophersolan Oral".WebMD.

[4] "Vedrop Summary of Product Characteristics "(PDF).European Medicines Agency.^{[permanent dead link]}

[5] Ash M, Ash I (2004).Handbook of Preservatives.Synapse Info Resources. p. 568.ISBN 1-890595-66-7.

[1]

[2]

[3]

[4]

[5]